Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Intimation Of The 174Th Board Meeting

 Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2019 ,inter alia, to consider and approve We wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, November 11, 2019 at 3:00 P.M. at the Registered Office of the Company interalia to discuss, consider and approve the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2019.
01-11-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Half Yearly Certificate Under Regulations 40(9) & 40(10) Of SEBI Listing Regulations, 2015.

 We furnish hereunder the certificate for the half year ended September 30, 2019 of Fredun Pharmaceuticals Limited under Regulations 40(9) & 40(10) of SEBI Listing Regulations, 2015; as issued by Rajendra & Co., Practising Company Secretaries.
22-10-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Regulation 7(3) Compliance Certificate For Half Year Ended Sept 2019

 In compliance to Regulation 7(3) of SEBI Listing Regulations, 2015; we furnish hereunder the Certificate, duly signed by the Company Secretary of Fredun Pharmaceuticals Limited and by the Compliance Officer of 'Purva Sharegistry (India) Pvt. Ltd.', designated Share Transfer Agent of the Company for the half year ended September 30, 2019.
17-10-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayFredun Pharmaceuticals Ltd 2CINL24239MH1987PLC043662 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 258689664.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRIYANKACHATURVEDI Designation: COMPANYSECRETARYCUMCOMPLIANCEOFFICER EmailId: PRIYANKA.CHATURVEDI@FREDUNGROUP.COM Name of the Chief Financial Officer: FREDUNMEDHORA Designation: MANAGINGDIRECTORCUMCFO EmailId: FREDUN@GMAIL.COM Date: 12/10/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
12-10-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Shareholding for the Period Ended September 30, 2019

 Fredun Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here
10-10-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In compliance to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder the confirmation certificate received from the SEBI Registered Share Transfer Agent viz. Purva Sharegistry (India) Pvt. Ltd. of the Company for the Quarter ended September 30, 2019.
10-10-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Statement Of Investor Complaints For The Quarter Ended September 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Priyanka ChaturvediDesignation :- Company Secretary and Compliance Officer
05-10-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Receipt Of Award

 We are happy to share with our stakeholders that your Company has received a Prestigious and a well-recognized award in the Pharma Sector 'Emerging Company of the Year 2019' from Zee Business Presents - National Healthcare Leadership Congress & Awards presented on Saturday, September 28, 2019.
30-09-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window

 The trading window for dealing in the securities of the Company will remain closed for designated persons and their immediate relatives with effect from October 1, 2019 till 48 hours after the end of the Board Meeting wherein; the approval of Un-Audited Financial Results for the Quarter and Half year ended September 30, 2019; would be considered, approved and declared.
30-09-2019
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Fredun Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
26-09-2019
Next Page
Close

Let's Open Free Demat Account